Patents by Inventor Weizhu Qian

Weizhu Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11014981
    Abstract: Provided are a method for preparing a new type of recombinant anti-TNF-? chimeric monoclonal antibody and a use. The method comprises: designing and synthesizing the light chain and heavy chain of a CMAB008 antibody according to the preferred codon of a hamster; constructing a eukaryotic expression vector; transfecting an CHO-CR-GS ?/? host cell with a GS knockout; and cultivating the cell using a serum-free culture technique; isolating and purifying; and thereby obtaining a low immunogenic CMAB008 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: May 25, 2021
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Publication number: 20200123244
    Abstract: Provided are a method for preparing a new type of recombinant anti-TNF-? chimeric monoclonal antibody and a use. The method comprises: designing and synthesizing the light chain and heavy chain of a CMAB008 antibody according to the preferred codon of a hamster; constructing a eukaryotic expression vector; transfecting an CHO-CR-GS -/- host cell with a GS knockout; and cultivating the cell using a serum-free culture technique; isolating and purifying; and thereby obtaining a low immunogenic CMAB008 antibody.
    Type: Application
    Filed: January 4, 2016
    Publication date: April 23, 2020
    Applicant: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Patent number: 10118966
    Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: November 6, 2018
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Publication number: 20180030139
    Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
    Type: Application
    Filed: January 4, 2016
    Publication date: February 1, 2018
    Inventor: Weizhu Qian
  • Publication number: 20100311955
    Abstract: The present invention provides a humanized anti-human CD34 antibody and the preparation method thereof. The humanized anti-human CD34 antibody retains the affinity and specificity of its original murine-derived antibody. The antibody can be conjugated with magnetic nano materials to prepare immunomagnetic beads to screen marrow hemopoietic stem cells. It can effectively reduce the incidence rate of HAMA and improve the security of clinical transplantation of hemopoietic stem cells and can be used in treatment of certain malignant hematologic diseases and solid tumors.
    Type: Application
    Filed: December 3, 2008
    Publication date: December 9, 2010
    Applicant: Shanhai Guojian Bio-Tech Institute
    Inventors: Yajun Guo, Weizhu Qian, Sheng Hou, Bohua Li, Hao Wang, Jing Ma
  • Publication number: 20100239588
    Abstract: The present invention discloses the functional epitope of osteopontin; the anti-osteopontin monoclonal antibody and immune conjugate raising against the functional epitope and their use for preparing anti-tumor drug. The present invention also discloses the DNA sequence encoding the monoclonal antibody, the vector and host cell containing the DNA sequence. The monoclonal antibody and immune conjugate of present invention can also be used to detect OPN. Through inhibiting OPN, the monoclonal antibody or immune conjugate of present invention can remedy or respite autoimmune diseases and protect correlative tissues, so they can be used to remedy autoimmune diseases.
    Type: Application
    Filed: March 25, 2008
    Publication date: September 23, 2010
    Applicant: Shanghai National Engineering Research Center of Antibody Medicine Co.
    Inventors: Yajun Guo, Jianxin Dai, Hao Wang, Geng Kou, Shang Hou, Weizhu Qian, Kexing Fan
  • Publication number: 20100151486
    Abstract: Provided are functional epitopes of osteopontin (OPN), monoclonal antibodies that specifically bind to the epitopes, immunoconjugates comprising the monoclonal antibodies and use of the monoclonal antibodies or immunoconjugates for manufacturing a medicament for the treatment of tumor. Also provided are nucleotide sequences encoding the monoclonal antibodies and vectors and host cells comprising the sequences. The monoclonal antibodies or immunoconjugates can be used for detecting the OPN, blocking the promoting metastasis-signaling pathway mediated by OPN and preventing the development and metastasis of tumor, thereby inhibiting the tumor.
    Type: Application
    Filed: March 25, 2008
    Publication date: June 17, 2010
    Applicant: SHANGHAI NATIONAL ENGINEERING RESEARCH CENTER OF A
    Inventors: Yajun Guo, Jianxin Dai, Hao Wang, Geng Kou, Shang Hou, Weizhu Qian, Ling Peng